Total Lymphoid Irradiation Pre-HSCT in Severe Congenital Neutropenia

Status Not yet recruiting

Clinical Trial Summary

Severe congenital neutropenia (SCN) is a group of primary immunodeficiencies caused by distinct gene mutations and characterized by neutrophil maturation impairment, which leads to neutropenia, predisposition to severe bacterial and fungal infections, and myeloid malignancies. Granulocyte-colony stimulation factor is used for pathogenetic therapy, however, no adequate response is seen in some patients. The only curative option for SCN is hematopoietic stem cell transplantation (HSCT). An indication for HSCT in SCN is: no adequate response to G-CSF therapy, or development of malignancies, or found unfavorable mutations of SCN genes, leading to poor response to G-CSF and high risk of malignant transformation. One of the major peculiarities of HSCT in SCN is a high risk of graft failure. That was described in few studies in SCN transplantation and was also observed in our SCN HSCT cohort. We also consider the role of TCRab/CD19 graft depletion, which is routinely used in our center for GVHD prophylaxis in increased risks of graft failure. Another problem often observed in our patients is the relatively high risks of death of infections, developed after graft failure. Due to predominantly early HSCT graft failure development, non-sufficient immuablation is presumed as the main reason for graft failure. Because of the low level of toxicity, associated with TCRab/CD19 depletion usage, this strategy is planned to be used in the current study. To increase an immunoablative potential of conditioning regimen in SCN, total lymphoid irradiation will be studied in combination with myeloablative agents and standardly used serotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04844177
Study type	Interventional
Source	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact	Dmitry Balashov, MD, PhD
Phone	84956647078
Email	Dmitriy.Balashov@fccho-moscow.ru
Status	Not yet recruiting
Phase	Phase 2
Start date	April 14, 2021
Completion date	April 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT02179359` - Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	N/A
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Active, not recruiting	`NCT01966367` - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation	Phase 1/Phase 2
Completed	`NCT00176852` - Stem Cell Transplant for Hemoglobinopathy	Phase 2/Phase 3
Recruiting	`NCT02720679` - Investigation of the Genetics of Hematologic Diseases
Completed	`NCT01917708` - Bone Marrow Transplant With Abatacept for Non-Malignant Diseases	Phase 1
Completed	`NCT00301834` - Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders	Phase 2
Completed	`NCT01529827` - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Completed	`NCT00305708` - Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission	Phase 1/Phase 2
Completed	`NCT00295971` - Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.